Author

Omar S. Al‐Odat

Cooper Medical School of Rowan UniversityORCID 0000-0002-9563-6030Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

Aaliyah BattleiD· 1 shared Arnold BolomskyiD· 1 shared Björn HäupliD· 1 shared Callie K. VanWinkleiD· 1 shared Elizabeth HilliD· 1 shared Gavin P. RobertsoniD· 1 shared Jagan R. MuppidiiD· 1 shared Jaikee Kumar SinghiD· 1 shared

Activity by Year

2022-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaliyah BattleORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation

Lin Zhang, Arnold Bolomsky, Omar S. Al‐Odat, Callie K. VanWinkle, Aaliyah Battle, Papiya Chakraborty, Ronald J. Holewinski, Þorkell Andrésson, Björn Häupl, Thomas Oellerich, Elizabeth Hill, Mehmet Hakan Kocoglu, Qingcai Meng, James D. Phelan, Jagan R. Muppidi, Ryan M. Young

This study identifies phosphorylation as a mechanism protecting oncogenic RAS from LZTR1-mediated degradation, with implications for targeting RAS stability in hematologic cancers.

Blood Cancer Discovery · Aug 31, 2026Peer-reviewedCancer Biology

Development of a Novel Bruton's Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells

Weam Othman Elbezanti, Omar S. Al‐Odat, Robert J. Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan, Manoj Kumar Pandey

This paper develops a novel BTK inhibitor, KS151, which effectively targets MM stem cell-like cells and enhances the response to chemotherapeutic agents.

Frontiers in Pharmacology · Sep 9, 2022Peer-reviewedMolecular Biology